These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 12566907)

  • 21. Drug-administration sequence does not change pharmacodynamics and kinetics of irinotecan and cisplatin.
    de Jonge MJ; Verweij J; Planting AS; van der Burg ME; Stoter G; de Boer-Dennert MM; de Bruijn P; Brouwer E; Vernillet L; Sparreboom A
    Clin Cancer Res; 1999 Aug; 5(8):2012-7. PubMed ID: 10473080
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical pharmacokinetics of irinotecan.
    Chabot GG
    Clin Pharmacokinet; 1997 Oct; 33(4):245-59. PubMed ID: 9342501
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors.
    Herben VM; Schellens JH; Swart M; Gruia G; Vernillet L; Beijnen JH; ten Bokkel Huinink WW
    J Clin Oncol; 1999 Jun; 17(6):1897-905. PubMed ID: 10561231
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer.
    DeVore RF; Johnson DH; Crawford J; Garst J; Dimery IW; Eckardt J; Eckhardt SG; Elfring GL; Schaaf LJ; Hanover CK; Miller LL
    J Clin Oncol; 1999 Sep; 17(9):2710-20. PubMed ID: 10561345
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer.
    Shinkai T; Arioka H; Kunikane H; Eguchi K; Sasaki Y; Tamura T; Ohe Y; Oshita F; Nishio M; Karato A
    Cancer Res; 1994 May; 54(10):2636-42. PubMed ID: 8168091
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer.
    Masuda N; Fukuoka M; Kudoh S; Kusunoki Y; Matsui K; Nakagawa K; Hirashima T; Tamanoi M; Nitta T; Yana T
    J Clin Oncol; 1994 Jan; 12(1):90-6. PubMed ID: 7505810
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.
    Pitot HC; Goldberg RM; Reid JM; Sloan JA; Skaff PA; Erlichman C; Rubin J; Burch PA; Adjei AA; Alberts SA; Schaaf LJ; Elfring G; Miller LL
    Clin Cancer Res; 2000 Jun; 6(6):2236-44. PubMed ID: 10873073
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma: a pilot phase II clinical trial and pharmacokinetic profile.
    Nakano T; Chahinian AP; Shinjo M; Togawa N; Tonomura A; Miyake M; Ninomiya K; Yamamoto T; Higashino K
    Cancer; 1999 Jun; 85(11):2375-84. PubMed ID: 10357408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Irinotecan plus cisplatin therapy and S-1 plus cisplatin therapy for advanced or recurrent gastric cancer in a single institution.
    Nakashima K; Hironaka S; Boku N; Onozawa Y; Fukutomi A; Yamazaki K; Yasui H; Taku K; Kojima T; Machida N
    Jpn J Clin Oncol; 2008 Dec; 38(12):810-5. PubMed ID: 18988666
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Pharmacokinetic study of CPT-11, SN-38 and SN-38 glucuronide in the ascites, plasma and bile after intraperitoneal administration of CPT-11].
    Natsui S; Maruyama M; Ochiai T; Hasegawa K; Takashima I; Nagahama T; Ebuchi M
    Gan To Kagaku Ryoho; 2002 Nov; 29(12):2188-90. PubMed ID: 12484033
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sparse-data set analysis for irinotecan and SN-38 pharmacokinetics in cancer patients co-treated with cisplatin.
    Mathijssen RH; van Alphen RJ; de Jonge MJ; Verweij J; de Bruijn P; Loos WJ; Nooter K; Vernillet L; Stoter G; Sparreboom A
    Anticancer Drugs; 1999 Jan; 10(1):9-16. PubMed ID: 10194542
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study.
    Ajani JA; Baker J; Pisters PW; Ho L; Mansfield PF; Feig BW; Charnsangavej C
    Cancer; 2002 Feb; 94(3):641-6. PubMed ID: 11857295
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I study of a weekly infusion of irinotecan hydrochloride (CPT-11) and a 14-day continuous infusion of etoposide in patients with lung cancer: JCOG trial 9408.
    Fujishiro M; Shinkai T; Fukuda M; Tamura T; Ohe Y; Kunitoh H; Nishiwaki Y; Sekine I; Fukuda H; Saijo N
    Jpn J Clin Oncol; 2000 Nov; 30(11):487-93. PubMed ID: 11155918
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancy.
    Licitra EJ; Vyas V; Nelson K; Musanti R; Beers S; Thomas C; Poplin E; Smith S; Lin Y; Schaaf LJ; Aisner J; Gounder M; Rajendra R; Saleem A; Toppmeyer D; Rubin EH
    Clin Cancer Res; 2003 May; 9(5):1673-9. PubMed ID: 12738720
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activity and safety of a low dose, fractional administration of irinotecan hydrochloride (CPT-11) in combination with cisplatin for relapsed gastric cancer patients: a preliminary report.
    Shimoyama S; Aoki F; Shimizu N; Tatsutomi Y; Mafune K; Kaminishi M
    Int J Clin Oncol; 2003 Feb; 8(1):49-52. PubMed ID: 12601543
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Combination of irinotecan hydrochloride (CPT-11) and cisplatin as a new regimen for patients with advanced ovarian cancer].
    Sugiyama T; Nishida T; Kataoka A; Imaishi K; Komai K; Ushijima K; Hasuo Y; Ookura N; Yakushiji M
    Nihon Sanka Fujinka Gakkai Zasshi; 1996 Sep; 48(9):827-34. PubMed ID: 8841050
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Efficacy of low-dose CDDP and CPT-11 for patients with intestinal type of gastric adenocarcinoma].
    Nagahori Y; Nagahori K; Hamaguchi Y; Fukushima T; Masui H; Mogaki M; Abe T
    Gan To Kagaku Ryoho; 2008 Sep; 35(9):1555-9. PubMed ID: 18799911
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Simple and rapid determination of irinotecan and its metabolite SN-38 in plasma by high-performance liquid-chromatography: application to clinical pharmacokinetic studies.
    Escoriaza J; Aldaz A; Castellanos C; Calvo E; Giráldez J
    J Chromatogr B Biomed Sci Appl; 2000 Apr; 740(2):159-68. PubMed ID: 10821401
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks.
    Rothenberg ML; Kuhn JG; Schaaf LJ; Rodriguez GI; Eckhardt SG; Villalona-Calero MA; Rinaldi DA; Hammond LA; Hodges S; Sharma A; Elfring GL; Petit RG; Locker PK; Miller LL; von Hoff DD
    Ann Oncol; 2001 Nov; 12(11):1631-41. PubMed ID: 11822765
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of prolonged-release CPT-11-loaded microspheres in rats.
    Machida Y; Onishi H; Kurita A; Hata H; Morikawa A; Machida Y
    J Control Release; 2000 May; 66(2-3):159-75. PubMed ID: 10742577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.